首页/数据集/Oncogenic MTOR signaling axis compensates BTK inhibition in a Chronic Lymphocytic Leukemia patient

Oncogenic MTOR signaling axis compensates BTK inhibition in a Chronic Lymphocytic Leukemia patient

NIAID Data Ecosystem2026-03-13 收录

BTK抑制剂

慢性淋巴细胞白血病转录组分析

数据链接：

https://www.ncbi.nlm.nih.gov/bioproject/PRJNA839176 数据链接链接失效反馈

官方服务：

资源简介：

Mutation and transcriptome analysis and of an ibrutinib resistant patient.

应用场景：

创建时间：

2022-05-18

BTK抑制剂

药物耐药性

Despite significant efficacy, one of the major limitations of small-molecule Bruton’s tyrosine kinase (BTK) agents is the presence of clinically acquired resistance, which remains a major clinical cha

Figshare2022-05-20 更新40

Brutons tyrosine kinase in complex with compound 50.

BTK抑制剂

结构生物学

Brutons tyrosine kinase in complex with compound 50. Descriptor: 1,2-ETHANEDIOL, N-[2-fluoro-6-(pyrrolidin-1-yl)phenyl]-N'-{3-[(2R)-1-(2-hydroxyethyl)-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazin-2-yl

Protein Data Bank Japan2024-03-13 更新30

Co-crystal structure of BTK kinase domain with Zanubrutinib

BTK抑制剂

结构生物学

Co-crystal structure of BTK kinase domain with Zanubrutinib Descriptor: (7S)-2-(4-phenoxyphenyl)-7-(1-propanoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, IMIDAZOLE, Tyr

Protein Data Bank Japan2024-10-23 更新20

Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton’s Tyrosine Kinase

BTK抑制剂

淋巴细胞恶性肿瘤治疗

Although Bruton’s tyrosine kinase (BTK) has been recognized as a validated drug target for the treatment of B-cell malignances, the emergence of clinical resistance to the first-generation covalent BT

NIAID Data Ecosystem40

Clonal Evolution underlying leukemia progression and Richter transformation in ibrutinib-relapsed CLL patients

白血病克隆演化

BTK抑制剂

Serial samples from CLL patients who relapsed post treatment with BTK-inhibitor, Ibrutinib (Ibr), sequenced using UCM-OncoPlus (a 1200 hybrid capture gene panel from University of Chicago)

NIAID Data Ecosystem30

Oncogenic MTOR signaling axis compensates BTK inhibition in a Chronic Lymphocytic Leukemia patient

资源简介：

相关数据集